COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls

COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls

Abstract Objective To estimate risks for all‐cause mortality and for severe COVID‐19 in multiple sclerosis patients and across relapsing–remitting multiple sclerosis patients exposed to disease‐modifying therapies. Methods We conducted a Swedish nationwide population‐based multi‐register linkage coh...

Full description

Bibliographic Details
Main Authors: Elisa Longinetti, Hannah Bower, Kyla A McKay, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell‐Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer‐Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Johan Mellergård, Tomas Olsson, Fredrik Piehl, Thomas Frisell
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:Annals of Clinical and Translational Neurology
Online Access:https://doi.org/10.1002/acn3.51646

Internet

https://doi.org/10.1002/acn3.51646

Similar Items